Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
The Effects of Turkish Coffee and Green Tea Consumption on Liver Steatosis Level and Biochemical Parameters in Individuals With Non-Alcoholic Fatty Liver Disease
1 other identifier
interventional
47
1 country
1
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors. This study aims to evaluate the effects of Turkish coffee and green tea consumption in addition to a Mediterranean diet intervention on liver fat content, biochemical parameters, and anthropometric measurements in individuals with fatty liver disease. Participants received a 12-week Mediterranean diet program and were assigned to groups consuming Turkish coffee, green tea, or no additional beverage intervention. Changes in liver ultrasonography findings, liver enzymes, metabolic parameters, and body measurements were evaluated before and after the intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2025
CompletedFirst Submitted
Initial submission to the registry
August 4, 2026
CompletedFirst Posted
Study publicly available on registry
August 17, 2026
CompletedAugust 17, 2026
July 1, 2026
11 months
August 4, 2026
August 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in liver steatozis grade by abdominal Ultrasonography
Liver steatosis was assessed by abdominal ultrasonography and graded as Grade 0 (no steatosis), Grade 1 (mild steatosis), Grade 2 (moderate steatosis), and Grade 3 (severe steatosis). Higher grades indicate greater severity of hepatic steatosis.
Baseline and 12 weeks
Secondary Outcomes (3)
Change in Alanine Aminotransferase (ALT) Level (U/L)
Baseline and 12 Weeks
Change in Aspartate Aminotransferase (AST) Level (U/L)
Baseline and Week 12
Change in Gamma-Glutamyl Transferase (GGT) Level (U/L)
Baseline and Week 12
Other Outcomes (9)
Change in Body Weight (kg)
Baseline and Week 12
Change in Body Mass Index (BMI) (kg/m²)
Baseline and Week 12
Change in Waist Circumference (cm)
Baseline and Week 12
- +6 more other outcomes
Study Arms (3)
Mediterranean Diet + Green Tea
EXPERIMENTALParticipants received a Mediterranean diet intervention and consumed green tea three times daily as an adjunct to the diet for 12 weeks.
Mediterranean Diet + Turkish Coffee
EXPERIMENTALParticipants received a Mediterranean diet intervention and consumed Turkish coffee twice daily for 12 weeks
Mediterranean Diet Control
ACTIVE COMPARATORParticipants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks.
Interventions
Participants consumed green tea three times daily as an adjunct to a Mediterranean diet intervention for 12 weeks.
Participants consumed Turkish coffee twice daily as an adjunct to a Mediterranean diet intervention for 12 weeks.
participants received a Mediterranean diet intervention without additional Turkish coffee or green tea consumption for 12 weeks.
Eligibility Criteria
You may qualify if:
- Participants aged 19-65 years with a diagnosis of non-alcoholic fatty liver disease (NAFLD).
- Not using medications for diabetes, dyslipidemia, or rheumatoid arthritis.
- Not using dietary supplements.
- No dietary program followed within the previous month.
- No severe psychiatric disorders.
- Willingness to participate in the study and provide informed consent.
You may not qualify if:
- Presence of diabetes, dyslipidemia, or rheumatoid arthritis.
- Alcohol consumption.
- Positive hepatitis B surface antigen (HBsAg), hepatitis C positivity, autoimmune hepatitis, liver cirrhosis, toxic hepatitis, or alanine aminotransferase (ALT) levels ≥10 times the upper limit of normal.
- Presence of liver malignancy or hepatic decompensation.
- Use of systemic corticosteroids or methotrexate within the previous 6 months.
- Pregnancy or lactation.
- Regular use of dietary supplements.
- Following a dietary program within the previous month.
- Presence of severe psychiatric disorders.
- High daily consumption of tea and coffee.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Okan Universitylead
Study Sites (1)
Istanbul Dr. Lutfi Kirdar City Hospital
Istanbul, Istanbul, 34865, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hande Öngün Yılmaz, PhD
BANDIRMA ONYEDI EYLUL UNIVERSITY, BANDIRMA VOCATIONAL SCHOOL
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2026
First Posted
August 17, 2026
Study Start
September 25, 2024
Primary Completion
August 15, 2025
Study Completion
August 15, 2025
Last Updated
August 17, 2026
Record last verified: 2026-07